Business Context and Reporting Period
This Form 6-K was filed on May 15, 2018, by GlaxoSmithKline plc, GlaxoSmithKline Capital plc, and GlaxoSmithKline Capital Inc. The filing serves to incorporate specific legal exhibits by reference into the registrants' Registration Statement on Form F-3 (File Nos. 333-223982, 333-223982-01, and 333-223982-02).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding legal instruments rather than a financial results report.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing details the execution of supplemental indentures dated May 15, 2018, involving Deutsche Bank Trust Company Americas as the trustee.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of risks and contingencies. It strictly lists the incorporation of the Second and Third Supplemental Indentures and legal opinions from Cleary Gottlieb Steen & Hamilton LLP.
Investor Verification Checklist
- Verify the terms of the Second and Third Supplemental Indentures referenced in Exhibits 4.1 and 4.2.
- Confirm the details of the Registration Statement on Form F-3 (File Nos. 333-223982 series) into which this report is incorporated.
- Review the legal opinions provided by Cleary Gottlieb Steen & Hamilton LLP (Exhibits 5.1 and 5.2) regarding the validity of the indentures.